The HER2 I655V polymorphism and breast cancer risk in Ashkenazim

Keyphrases

• Breast Cancer Risk 100%
• Polymorphism 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• Ashkenazi 100%
• Confidence Interval 50%
• Family History 33%
• Young Women 33%
• Ethnic Groups 16%
• Poor Prognosis 16%
• Young Age 16%
• Community-based Study 16%
• Cancer-related 16%
• Overexpression 16%
• First-degree Relatives 16%
• 50 Years Old 16%
• Patients with Breast Cancer 16%
• Age-specific 16%
• Breast Cancer Family History 16%
• Female Patients 16%
• Valine 16%
• Oncogene 16%
• Mutation Carriers 16%
• BRCA1, BRCA2 16%
• History Data 16%
• Non-carriers 16%
• Washington DC 16%
• Cohort Method 16%
• Age Estimation 16%
• Cumulative Risk 16%
• Germline Polymorphism 16%
• HER2 mutation 16%

Biochemistry, Genetics and Molecular Biology

• Allele 100%
• Epidermal Growth Factor Receptor 33%
• Germline 33%
• Germ Cell 33%
• BRCA1 33%
• Valine 33%
• Proto Oncogene 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Disease 12%
• Epidermal Growth Factor Receptor 2 12%
• Gamma Urogastrone 12%
• Valine 12%